- Home
- VGI vs AGEN Comparison
VGI vs AGEN Comparison
Compare VGI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- AGEN
- Stock Information
- Founded
- VGI 2012
- AGEN 1994
- Country
- VGI United States
- AGEN United States
- Employees
- VGI N/A
- AGEN N/A
- Industry
- VGI Investment Managers
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VGI Finance
- AGEN Health Care
- Exchange
- VGI Nasdaq
- AGEN Nasdaq
- Market Cap
- VGI 88.2M
- AGEN 96.2M
- IPO Year
- VGI N/A
- AGEN 2000
- Fundamental
- Price
- VGI $7.74
- AGEN $1.51
- Analyst Decision
- VGI
- AGEN Buy
- Analyst Count
- VGI 0
- AGEN 4
- Target Price
- VGI N/A
- AGEN $8.00
- AVG Volume (30 Days)
- VGI 46.0K
- AGEN 484.8K
- Earning Date
- VGI 01-01-0001
- AGEN 03-11-2025
- Dividend Yield
- VGI 12.66%
- AGEN N/A
- EPS Growth
- VGI N/A
- AGEN N/A
- EPS
- VGI N/A
- AGEN N/A
- Revenue
- VGI N/A
- AGEN $103,463,000.00
- Revenue This Year
- VGI N/A
- AGEN $32.21
- Revenue Next Year
- VGI N/A
- AGEN N/A
- P/E Ratio
- VGI N/A
- AGEN N/A
- Revenue Growth
- VGI N/A
- AGEN N/A
- 52 Week Low
- VGI $6.68
- AGEN $1.44
- 52 Week High
- VGI $7.99
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- VGI 41.76
- AGEN 21.95
- Support Level
- VGI $7.71
- AGEN $1.55
- Resistance Level
- VGI $7.82
- AGEN $1.77
- Average True Range (ATR)
- VGI 0.06
- AGEN 0.14
- MACD
- VGI -0.01
- AGEN 0.02
- Stochastic Oscillator
- VGI 26.79
- AGEN 9.85
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the global bond markets.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).